IP Library › Granted Patent US 9,040,515

Granted Patent B2

US 9,040,515 · App. 14/132,567 · Granted May 26, 2015

Aryl and heteroaryl fused lactams

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,040,515
App. No.: 14/132,567
Granted: May 26, 2015
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This invention relates to compounds of general formula (I) in which R 1 , R 2 , U, V, L, M, R 5 , m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Claims (89)

1. A compound of formula (II):

or a pharmaceutically acceptable salt thereof,

wherein:

U is N or CR 3 ;

V is N or CR 4 ;

R 1 is C 1 -C 8 alkyl, C 1 -C 8 alkoxy, halo, —OH, —CN or —NR 7 R 8 , where each said C 1 -C 8 alkyl or C 1 -C 8 alkoxy is optionally substituted by one or more R 21 ;

R 2 is selected from the group consisting of H, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, —OR 6 , —NR 7 R 8 , —C(O)NR 7 R 8 , —SO 2 NR 7 R 8 , —NR 7 SO 2 R 8 , C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl, where each said C 1 -C 8 alkyl or C 1 -C 8 alkoxy is optionally substituted by one or more R 22 , and each said C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl or 5-12 membered heteroaryl is optionally substituted by one or more R 32 ;

R 3 is H, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, halo, —OH, —CN or —NR 7 R 8 , where each said C 1 -C 8 alkyl or C 1 -C 8 alkoxy is optionally substituted by one or more R 23 ;

R 4 is selected from the group consisting of H, halo, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, 5-12 membered heteroaryl, —(C 1 -C 4 alkyl)R z , —OR x , —CN, —C(O)R x , —CO 2 R x , —C(O)NR x R y , —SR x , —SOR x , —SO 2 R x , —SO 2 NR x R y , —NO 2 , —NR x R y , —NR x C(O)R y , —NR x C(O)NR x R y , —NR x C(O)OR y , NR x SO 2 R y , —NR x SO 2 NR x R y , —OC(O)R x and —OC(O)NR x R y ;

each R x and R y is independently selected from the group consisting of H, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl; or R x and R y may be taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S;

each R z is independently selected from the group consisting of C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl; and

wherein each said C 1 -C 8 alkyl in R 4 , R x or R y and each said C 1 -C 4 alkyl in (C 1 -C 4 alkyl)R z is optionally substituted by one or more R 24 , and each said C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, or 5-12 membered heteroaryl in R 4 , R x , R y , R z , or R x and R y taken together is optionally substituted by one or more R 34 ;

each R 5 is independently selected from the group consisting of halo, —OH, ═O, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —CN, —NR 9 R 10 and —C(O)NR 9 R 10 , where each said C 1 -C 4 alkyl or C 1 -C 4 alkoxy is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halo, —OH, C 1 -C 4 alkoxy, —CN, —NR 9 R 10 and —C(O)NR 9 R 10 ;

R 6 is —(CR 11 R 12 ) n —R 13 ;

each R 7 and R 8 is independently selected from the group consisting of H, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, and 5-12 membered heteroaryl; or

R 7 and R 8 may be taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S;

where each said C 1 -C 8 alkyl in R 7 or R 8 is optionally substituted by one or more R 27 , and each said C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, or 5-12 membered heteroaryl in R 7 , R 8 , or R 7 and R 8 taken together is optionally substituted by one or more R 37 ;

each R 9 and R 10 is independently H or C 1 -C 4 alkyl; or

R 9 and R 10 may be taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S;

where each said C 1 -C 4 alkyl in R 9 or R 10 , and each said 3-12 membered heterocyclyl or 5-12 membered heteroaryl in R 9 and R 10 taken together is optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, —OH, ═O, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —CN, —NH 2 , —NH(C 1 -C 4 alkyl) and —N(C 1 -C 4 alkyl) 2 ;

each R 11 and R 12 is independently H, halo or C 1 -C 4 alkyl, where each said C 1 -C 4 alkyl is optionally substituted by one or more R 22 ;

R 13 is selected from the group consisting of C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, and 5-12 membered heteroaryl, where each said C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl or 5-12 membered heteroaryl is optionally substituted by one or more R 32 ;

m is 0 to 4;

n is 0 to 4;

each R 21 , R 22 , R 23 and R 24 is independently selected from the group consisting of halo, C 1 -C 8 alkyl, —CN, ═O, —C(O)R e , —CO 2 R e , —C(O)NR e R f , —OR e , —SR e , —SOR e , —SO 2 R e , —SO 2 NR e R f , —NO 2 , —NR e R f , —NR e C(O)R f , —NR e C(O)NR e R f , —NR e C(O)OR f —NR e SO 2 R f , —NR e SO 2 NR e R f , —OC(O)R e , —OC(O)NR e R f , C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl;

each R e and R f is independently selected from the group consisting of H, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl; or

R e and R f may be taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S;

wherein each said C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl or 5-12 membered heteroaryl in R 24 , R e , R f , or R e and R f taken together is optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, —OH, ═O, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 4 alkoxy-C 1 -C 6 alkyl, —CN, —NH 2 , —NH(C 1 -C 4 alkyl) and —N(C 1 -C 4 alkyl) 2 ;

each R 27 is independently selected from the group consisting of halo, —OH, C 1 -C 4 alkoxy, —CN, —NR 9 R 10 , C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl, where each said C 1 -C 4 alkoxy, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl or 5-12 membered heteroaryl is optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, —OH, ═O, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 4 alkoxy-C 1 -C 6 alkyl, —CN, —NH 2 , —NH(C 1 -C 4 alkyl) and —N(C 1 -C 4 alkyl) 2 ;

each R 32 , R 34 and R 37 is independently selected from the group consisting of halo, C 1 -C 8 alkyl, —CN, ═O, —C(O)R c , —CO 2 R c , —C(O)NR c R d , —OR c , —SR c , —SOR c , —SO 2 R c , —SO 2 NR c R d , —NO 2 , —NR c R d , —NR c C(O)R d , —NR c C(O)NR c R d , —NR c C(O)OR d , —NR c SO 2 R d , —NR c SO 2 NR c R d , —OC(O)R c , —OC(O)NR c R d , C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl;

each R c and R d is independently selected from the group consisting of H, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl; or

R c and R d may be taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl ring, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S;

wherein each said C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl or 5-12 membered heteroaryl in R 32 , R 34 , R 37 , R c , R d , or R c and R d taken together is optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, —OH, ═O, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 4 alkoxy-C 1 -C 6 alkyl, —CN, —NH 2 , —NH(C 1 -C 4 alkyl) and —N(C 1 -C 4 alkyl) 2 ;

X and Z are independently selected from the group consisting of H, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, 5-12 membered heteroaryl, halo, CN, —C(O)R a , —CO 2 R a , —C(O)NR a R b , —SR a , —SOR a , —SO 2 R a , —SO 2 NR a R b , —NO 2 , —NR a R b , —NR a C(O)R b , —NR a C(O)NR a R b , —NR a C(O)OR a , —NR a SO 2 R b , —NR a SO 2 NR a R b —OR a , —OC(O)R a or —OC(O)NR a R b ;

wherein each said C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, or 5-12 membered heteroaryl group is optionally substituted by one or more substituents independently selected from the group consisting of halo, —CN, —C(O)R a , —CO 2 R a , —C(O)NR a R b , —SR a , —SOR a , —SO 2 R a , —SO 2 NR a R b , —NO 2 , —NR a R b , —NR a C(O)R b , —NR a C(O)NR a R b , —NR a C(O)OR a —NR a SO 2 R b , —NR a SO 2 NR a R b , —OR a , —OC(O)R a , —OC(O)NR a R b , C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, and 5-12 membered heteroaryl;

each R a and R b is independently H, C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl or 5-12 membered heteroaryl, where each said C 1 -C 8 alkyl, C 2 -C 8 alkenyl, C 2 -C 8 alkynyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl is optionally substituted by one or more substituents independently selected from the group consisting of halo, C 1 -C 4 alkyl, —OR 14 , —NR 14 2 , —CO 2 R 14 , —C(O)NR 14 2 , —SO 2 R 14 and —SO 2 NR 14 2 , where each R 14 is independently H or C 1 -C 4 alkyl; or

R a and R b may be taken together with the N atom to which they are attached to form a 3-12 membered heterocyclyl or 5-12 membered heteroaryl, each optionally containing 1, 2 or 3 additional heteroatoms selected from O, N and S, wherein said heterocyclyl or heteroaryl is optionally substituted by one or more substituents independently selected from the group consisting of halo, —OH, ═O, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 4 alkoxy-C 1 -C 6 alkyl, —CN, —NH 2 , —NH(C 1 -C 4 alkyl) and —N(C 1 -C 4 alkyl) 2 ; and

Y is H, halo, —OH or C 1 -C 4 alkoxy.

2. The compound or salt of claim 1 , wherein U is CR 3 and V is CR 4 .

3. The compound or salt of claim 2 , wherein R 3 is H and R 4 is H or halo.

4. The compound or salt of claim 1 , wherein R 1 is C 1 -C 8 alkyl or halo.

5. The compound or salt of claim 1 , wherein R 2 is 5-12 membered heteroaryl, where said 5-12 membered heteroaryl is optionally substituted by 1 to 3 R 32 .

6. The compound or salt of claim 1 , wherein R 2 is OR 6 , where n is 0 or 1, and R 13 is 3-12 membered heterocyclyl or 5-12 membered heteroaryl, where each said 3-12 membered heterocyclyl or 5-12 membered heteroaryl is optionally substituted by 1 to 3 R 32 .

7. The compound or salt of claim 1 , wherein X and Z are independently selected from the group consisting of H, C 1 -C 8 alkyl and C 3 -C 8 cycloalkyl, and Y is H.

8. A compound of formula (II-A):

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is C 1 -C 8 alkyl, C 1 -C 8 alkoxy, halo, —OH, —CN or —NR 7 R 8 , where each said C 1 -C 8 alkyl or C 1 -C 8 alkoxy is optionally substituted by one or more R 21 ;

R 3 is H, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, halo, —OH, —CN or —NR 7 R 8 , where each said C 1 -C 8 alkyl or C 1 -C 8 alkoxy is optionally substituted by one or more R 23 ;

each R z is independently selected from the group consisting of C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl; and

R 6 is —(CR 11 R 12 ) n —R 13 ;

each R 7 and R 8 is independently selected from the group consisting of H, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl, and 5-12 membered heteroaryl; or

each R 9 and R 10 is independently H or C 1 -C 4 alkyl; or

each R 11 and R 12 is independently H, halo or C 1 -C 4 alkyl, where each said C 1 -C 4 alkyl is optionally substituted by one or more R 22 ;

m is 0 to 4;

n is 0 to 4;

each R e and R f is independently selected from the group consisting of H, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl; or

each R 32 , R 34 and R 37 is independently selected from the group consisting of halo, C 1 -C 8 alkyl, —CN, ═O, —C(O)R c , —CO 2 R c , —C(O)NR c R d , —SR c , —SOR c , —SO 2 R c , —SO 2 NR c R d , —NO 2 , —NR c R d , —NR c C(O)R d , —NR c C(O)NR c R d , —NR c C(O)OR d , —NR c SO 2 R d , —NR c SO 2 NR c R d , —OC(O)R c , —OC(O)NR c R d , C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl;

each R c and R d is independently selected from the group consisting of H, C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, 3-12 membered heterocyclyl, C 6 -C 12 aryl and 5-12 membered heteroaryl; or

Y is H, halo, —OH or C 1 -C 4 alkoxy.

9. The compound or salt of claim 8 , wherein R 1 is C 1 -C 8 alkyl or halo.

10. The compound or salt of claim 8 , wherein R 2 is 5-12 membered heteroaryl, where said 5-12 membered heteroaryl is optionally substituted by 1 to 3 R 32 .

11. The compound or salt of claim 10 , wherein each R 32 is independently selected from the group consisting of halo, C 1 -C 8 alkyl, —OR c , —SR c , —SO 2 R c and —NR c R d , and each R c and R d is independently H or C 1 -C 8 alkyl.

12. The compound or salt of claim 8 , wherein R 2 is OR 6 , n is 0 or 1, and R 13 is 3-12 membered heterocyclyl or 5-12 membered heteroaryl, where each said 3-12 membered heterocyclyl or 5-12 membered heteroaryl is optionally substituted by 1 to 3 R 32 .

13. The compound or salt of claim 12 , wherein each R 32 is independently selected from the group consisting of halo and C 1 -C 8 alkyl, where each said C 1 -C 8 alkyl is optionally substituted by 1 to 3 substituents independently selected from the group consisting of halo, —OH, ═O, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 4 alkoxy-C 1 -C 6 alkyl, —CN, —NH 2 , —NH(C 1 -C 4 alkyl) and —N(C 1 -C 4 alkyl) 2 .

14. The compound or salt of claim 8 , wherein R 3 is H and R 4 is selected from the group consisting of H, halo, —CN and C 1 -C 8 alkyl, where said C 1 -C 8 alkyl is optionally substituted by 1 to 3 R 24 .

15. The compound or salt of claim 8 , wherein X and Z are independently selected from the group consisting of H, C 1 -C 8 alkyl and C 3 -C 8 cycloalkyl, and Y is H.

16. The compound or salt of claim 8 , wherein m is 0.

17. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

Assignments (1)

ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023

From: PFIZER INC.

To: PFIZER INC.

Reel/Frame 063119/0087 →